James Green News

Seroba announces appointment of James L. Greene as CEO to MedLumics

Seroba Life Sciences announces the transition of James L. Greene from Partner in Seroba to the role of CEO in one of its portfolio companies, MedLumics.

A serial entrepreneur, Jim has founded and served as CEO for four medical device start-ups and currently serves as a member of the Wallace Coulter Oversight committee where he participates in the translation of innovative technologies from the Georgia Institute of Technology and Emory University, Atlanta, Georgia into successful new commercial ventures.  Additionally, he serves as Board Chairman of Novate Medical Limited, also a Seroba investee company.

As CEO and Founder of Galway-based start-up, Apica Cardiovascular, Jim developed a port access and closure system for delivering structural heart therapies which achieved CE Mark within 3 years of being established in Ireland, and which was subsequently sold to Thoratec Corporation.  As CEO of APK (Advanced Medical Technologies), Atlanta, Georgia, he developed a platform technology for delivery of mechanical circulatory support systems (LVADS) for congestive heart failure patients. APK was also acquired by Thoratec Corporation.  Previously, as CEO of Mitral Solutions in Fort Lauderdale, Florida, Jim steered the development of an innovative mitral valve repair device from concept through clinical trials, regulatory approval pathway and eventual sale of the company to St. Jude Medical.

Commenting on his appointment, James L. Greene said, “I’m excited to be taking on this new challenge with MedLumics. The company is developing exciting technology with the potential to revolutionise the treatment of atrial fibrillation.”

Speaking about the appointment to MedLumics, Peter Sandys, Managing Partner at Seroba said “We are delighted that Jim has agreed to take on the role of CEO as the company develops a breakthrough technology in Atrial Fibrillation.  We have worked with Jim on a variety of projects and know he’s the ideal person to steer MedLumics on this journey.  Jim has unparalleled experience in guiding start-up cardio-device companies to achieve their potential and we look forward to continuing to work with Jim on this exciting opportunity.”


For further information, please contact: Vicky La Touche-Price at Seroba on +353 16334028.

About MedLumics

Founded in 2009, MedLumics is an ISO13485 certified cardiology device company specializing in optically guided medical devices. Its proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multiview optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produce high-quality real-time images. The systems allow physicians to improve diagnostic and therapeutic procedures through a non-invasive optical evaluation of tissue.

MedLumics clinical and financial value proposition centers around its unique Optical Coherence Reflectometry (OCR) optical and sensing technology.   The AblaView® catheter, the Company’s initial product is a radio frequency ablation catheter for the treatment of atrial fibrillation.  It is the world’s first RF system, which incorporates miniaturized OCR technology into catheter tip and provides clinicians direct (not a surrogate marker) confirmation of lesion creation in “real-time”, which is not possible with other commercially available technologies.  The unique sensor technology also confirms contact and contact stability without the need to use force that can result in injury during ablation procedures, thus enhancing procedure safety as well as reducing procedure time.

MedLumics core OCR technology is a platform and has additional applications outside the field of atrial fibrillation allowing it to address unmet clinical needs across multiple large markets.


Recent Articles

Home V2

Seroba Invests in Storm Therapeutics

20 May 2019.  STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, has announced that […]

Read More
Quanta SC+

Quanta SC+ confirmed as safe and easy to use

Alcester, Warwickshire, UK, 15 April 2019.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a pioneering medical […]

Read More

Fusion Raises $105m in Series B Financing

April 2nd 2019. Hamilton, Canada and Dublin, Ireland.  Seroba’s portfolio company, Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle […]

Read More
Jen Moderator Session On Investment Cycles

VCs with €6Bn in Funds to Invest Visit Dublin

The sixth annual MedTech Strategist Innovation Summit Dublin will take place this April in the Shelbourne Hotel. Dozens of Venture […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19

Scroll to Top